Bristol-Myers Squibb Co
CELG_r0.030USD
0.000
Close 08/04, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Bristol-Myers Squibb Co Company
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
Company Info
Ticker SymbolCELG_r
Company nameBristol-Myers Squibb Co
IPO dateMar 17, 1980
CEODr. Christopher S. (Chris) Boerner, Ph.D.
Number of employees- -
Security type- -
Fiscal year-end- -
AddressRoute 206 And Province Line Road
CityPRINCETON
Stock exchange- -
CountryUnited States of America
Postal code08543
Phone16092524621
Websitehttps://www.bms.com
Ticker SymbolCELG_r
IPO dateMar 17, 1980
CEODr. Christopher S. (Chris) Boerner, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Michael R. (Mike) Mcmullen
Mr. Michael R. (Mike) Mcmullen
Independent Director
Independent Director
--
--
Mr. Benjamin Hickey
Mr. Benjamin Hickey
President - RayzeBio Organization, Member of the Leadership Team
President - RayzeBio Organization, Member of the Leadership Team
--
--
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Ms. Phyllis R. Yale
Ms. Phyllis R. Yale
Independent Director
Independent Director
--
--
Mr. Greg Scott Meyers
Mr. Greg Scott Meyers
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
--
--
Ms. Amanda Poole
Ms. Amanda Poole
Executive Vice President, Chief People Officer, Member of the Leadership Team
Executive Vice President, Chief People Officer, Member of the Leadership Team
--
--
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert Plenge, M.D., Ph.D.
Mr. Robert Plenge, M.D., Ph.D.
Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team
Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team
--
--
Dr. Karen H. Vousden, Ph.D.
Dr. Karen H. Vousden, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael R. (Mike) Mcmullen
Mr. Michael R. (Mike) Mcmullen
Independent Director
Independent Director
--
--
Mr. Benjamin Hickey
Mr. Benjamin Hickey
President - RayzeBio Organization, Member of the Leadership Team
President - RayzeBio Organization, Member of the Leadership Team
--
--
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Ms. Phyllis R. Yale
Ms. Phyllis R. Yale
Independent Director
Independent Director
--
--
Mr. Greg Scott Meyers
Mr. Greg Scott Meyers
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 30
Updated: Wed, Jul 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
33
482.65K
0.00%
-636.67K
2025Q1
32
482.82K
0.00%
-636.30K
2024Q4
32
943.43K
0.00%
+289.58K
2024Q3
31
601.53K
0.00%
-30.97K
2024Q2
30
511.50K
0.00%
+7.21K
2024Q1
32
397.74K
0.00%
-298.70K
2023Q4
30
495.62K
0.00%
-151.97K
2023Q3
30
535.93K
0.00%
-247.50K
2023Q2
31
542.98K
0.00%
-138.59K
2023Q1
34
441.11K
0.00%
-360.09K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Transcend Capital Advisors, LLC
109.17K
0%
-8.60K
-7.30%
Mar 31, 2025
Davenport Asset Management
83.97K
0%
--
--
Mar 31, 2025
Maven Investment Partners US Ltd.
67.86K
0%
--
--
Mar 31, 2025
BofA Global Research (US)
51.82K
0%
+180.00
+0.35%
Mar 31, 2025
Purkiss Capital Advisors LLC
26.45K
0%
--
--
Mar 31, 2025
Two Sigma Investments, LP
25.68K
0%
-465.00
-1.78%
Mar 31, 2025
MainStreet Advisors
20.00K
0%
--
--
Mar 31, 2025
Watts Gwilliam & Co LLC
20.00K
0%
--
--
Mar 31, 2025
Private Advisor Group LLC
15.00K
0%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
